MyUvealMelanoma.com was created for people who have just been diagnosed with this rare cancer. We provide a lot of information about the disease and its treatment, as well as great resources. But our main goal is to make patients aware of a genomic test that can help determine whether the tumor will metastasize, or spread to other parts of the body.
Up to half of uveal melanoma patients will ultimately develop fatal metastases, so monitoring and follow-up after eye surgery are critical. The prognostic test, DecisionDx-UM, is a highly accurate predictor of metastatic risk. It is being used by the majority of ocular oncologists to individualize their patients’ care plans after surgery with the hopes of earlier detection and intervention.
Our company, Castle Biosciences, works with leading cancer treatment centers to develop molecular tests like DecisionDx-UM to help patients and physicians achieve better outcomes in rare cancers. We strongly believe that it is up to each patient, in discussion with their doctor, to determine whether they want to know their metastatic risk. So we’ve dedicated this site to providing a comprehensive and factual basis for making that decision.